Minimal impact of IL-17 and IL-12/23 inhibition on SARS-CoV-2/COVID-19 antibody response in psoriasis patients.

Lavin, Leore; Ungar, Benjamin; Sa, Brianna; Guttman-Yassky, Emma

Lavin, Leore; Ungar, Benjamin; Sa, Brianna; Guttman-Yassky, Emma.

Afiliación

Lavin L; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Ungar B; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Sa B; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Guttman-Yassky E; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. emma.guttman@mountsinai.org.

Arch Dermatol Res ; 316(1): 5, 2023 11 21.

Article en En | MEDLINE | ID: mdl-37987858

Asunto(s)

Formación de Anticuerpos; COVID-19; Interleucina-12; Interleucina-17; Interleucina-23; Psoriasis; Humanos; COVID-19/complicaciones; COVID-19/inmunología; SARS-CoV-2; Psoriasis/complicaciones

Palabras clave

Antibodies; COVID-19; IL-12/23 inhibitors; IL-17 inhibitors; Immune response; Psoriasis; SARS-CoV-2

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis / Interleucina-12 / Interleucina-17 / Interleucina-23 / COVID-19 / Formación de Anticuerpos Límite: Humans Idioma: En Revista: Arch Dermatol Res Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google